Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. CHYM
3. BRZE
4. USO
5. QCOM
6. DYN
7. PHVS
8. NOVN:SW
9. USB
10. NVS

Go back to Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
(NASDAQ: IMUX) Delayed: 12.74 --0 (-0%)
Previous Close $12.74    52 Week High $ 
Open $12.74    52 Week Low $ 
Day High $12.74    P/E N/A 
Day Low $12.74    EPS $ 
Volume 225